What is Synakis?
Synakis operates at the intersection of advanced materials science and regenerative medicine. The company is primarily focused on the development of SNK-125, an innovative injectable hydrogel designed to treat complex ocular conditions, including retinal detachment and glaucoma. By leveraging biocompatible and biodegradable materials, Synakis aims to provide long-term, effective solutions for patients suffering from leading causes of blindness. The company's market position is defined by its rigorous scientific approach to ocular drug delivery, aiming to disrupt traditional treatment paradigms through precision engineering and a deep understanding of glycomics and biomaterial interactions. As a pre-clinical entity, Synakis maintains a strategic focus on de-risking its technology while building a robust intellectual property portfolio that supports its long-term commercialization goals.
How much funding has Synakis raised?
Synakis has raised a total of $1.9M across 1 funding round:
Angel/Pre-Seed
$1.9M
Angel/Pre-Seed (2026): $1.9M with participation from Ontario Centre of Innovation, Canadian Glycomics Network, and Toronto Innovation Acceleration Partners
Key Investors in Synakis
Ontario Centre of Innovation
A government-funded organization that drives the commercialization of cutting-edge research across key sectors, including advanced health and materials.
Canadian Glycomics Network
A specialized research network focused on developing carbohydrate-based drugs and diagnostics to address global health challenges.
Toronto Innovation Acceleration Partners
A venture builder specializing in early-stage health science technologies, providing expert financial and scientific advice to de-risk academic innovations.
What's next for Synakis?
With the recent infusion of capital, Synakis is poised to scale its laboratory operations and advance its pre-clinical studies for SNK-125. The strategic roadmap involves optimizing the hydrogel delivery mechanism to ensure maximum efficacy and safety in human applications. Furthermore, the company intends to leverage its partnerships with academic and research networks to refine its therapeutic candidates. As the firm moves toward clinical readiness, the focus will shift to regulatory engagement and the establishment of manufacturing protocols that meet international standards for ophthalmic medical devices. This phase of growth is critical for Synakis as it seeks to validate its technology in more complex models, ultimately aiming to secure future financing rounds that will support the transition into human clinical trials and long-term market entry.
See full Synakis company page
